{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:39:41Z","timestamp":1787240381196,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.eururo.2016.01.028","type":"journal-article","created":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T19:03:07Z","timestamp":1454526187000},"page":"718-721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer"],"prefix":"10.1016","volume":"70","author":[{"given":"Scott T.","family":"Tagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin M.","family":"Posadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson A.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Petrylak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thian","family":"Kheoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Maul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha D.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"De Porre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NamPhuong","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Nanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2016.01.028_bib0055","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.eururo.2011.04.038","article-title":"New therapies for castration-resistant prostate cancer: efficacy and safety","volume":"60","author":"Beltran","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.01.028_bib0060","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1158\/0008-5472.CAN-11-1417","article-title":"Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer","volume":"71","author":"Darshan","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2016.01.028_bib0065","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/1078-0432.CCR-14-1358","article-title":"Novel actions of next-generation taxanes benefit advanced stages of prostate cancer","volume":"21","author":"de Leeuw","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2016.01.028_bib0070","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1158\/0008-5472.CAN-09-1504","article-title":"Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer","volume":"69","author":"Gan","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2016.01.028_bib0075","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1158\/0008-5472.CAN-12-0783","article-title":"Androgen receptor on the move: boarding the microtubule expressway to the nucleus","volume":"72","author":"Thadani-Mulero","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2016.01.028_bib0080","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1158\/0008-5472.CAN-10-0585","article-title":"Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer","volume":"70","author":"Zhu","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2016.01.028_bib0085","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","author":"James","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2016.01.028_bib0090","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2016.01.028_bib0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/jco.2013.31.6_suppl.63","article-title":"Enzalutamide in combination with docetaxel in men with prostate cancer (PC): preliminary results from a phase I study [abstract]","volume":"31","author":"Fleming","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.01.028_bib0100","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10637-014-0199-x","article-title":"Phase 1\/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer","volume":"33","author":"Petrylak","year":"2015","journal-title":"Invest New Drugs"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816001305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816001305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T15:26:04Z","timestamp":1537025164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283816001305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0302283816001305"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2016.01.028","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2016.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}